Comparing the current results to its competitors, Dyadic International Inc reported Revenue decrease in the 2 quarter 2026 year on year by -0.57 %, despite the revenue increase by the most of its competitors of 11.19 %, recorded in the same quarter.
Dyadic International Inc 's Comment on Competition and Industry Peers
Dyadic operates in a competitive environment across multiple expression systems, including mammalian (CHO), bacterial (E. coli), yeast, and insect cells, serving life sciences applications such as cell culture media components and molecular biology reagents. In the food and nutrition sectors, competition is increasing due to advancements in precision fermentation and synthetic biology, with several companies developing recombinant proteins like caseins, whey components, and bioactive peptides. In the bio-industrial segment, Dyadic competes with multinational enzyme producers and microbial fermentation companies that develop enzymes for biomass conversion, pulp and paper, and biofuels. Dyadic collaborates with commercial partners such as Fermbox to facilitate market entry. Other competitors in the non-animal recombinant protein space utilize yeast platforms (Pichia and Saccharomyces) and filamentous fungal platforms (Aspergillus and Trichoderma). Academic institutions, contract development and manufacturing organizations (CDMOs), and government-funded initiatives also contribute to competition by advancing alternative production technologies or partnering with industry participants. Dyadic asserts that its platforms provide differentiation in scalability, productivity, cost efficiency, and glycan profiles; however, there is no guarantee of successful competition or that technological advancements by others will not impact Dyadic's market position.
June 28, 2024
Dyadic International, Inc., a prominent global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has recently partnered with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins, to develop and commercialize recombinant albumin. This collaboration aims to provide innovative solutions for diagnostic, nutrition, and cell culture markets, leveraging Dyadic s expertise in microbial platforms and PHB s experience in the supply of purified proteins.Partnership with Proliant Health and Biologicals:Dyadic International and Proliant Health and Biologicals have joined forces to develop and commercialize recombinant albumin. Proliant ...
March 26, 2024
Dyadic International, a renowned global biotechnology company, has recently achieved a significant milestone with the publication of their latest study in Nature Communications. The study s groundbreaking findings showcase the efficacy of Dyadic s C1 Monoclonal Antibody, which was produced using filamentous fungus, in providing protection against SARS-CoV-2. The results demonstrated its potential in hamster and nonhuman primate models, thereby offering promising advancements in the fight against the ongoing COVID-19 pandemic.With their primary focus on developing innovative microbial protein production platforms, Dyadic International stands at the forefront of biotechnological advancements. The company s dil...
February 28, 2024
Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, has recently made significant strides in its mission to provide accessible and affordable biopharmaceutical products for human and animal health. Through strategic partnerships and research collaborations, Dyadic aims to develop efficient rabies prophylactics and vaccines using its innovative C1 Cell Microbial Protein Production Platform. Additionally, the company has joined forces with Cygnus Technologies to enhance quality assurance in biomanufacturing by quantifying Host Cell Proteins (HCP) using the C1-cells filamentous fungus. These developments potentially signify a positive impact on Dyadic s future prospects and the global bu...
February 23, 2024
DYADIC AND ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH COLLABORATE TO TACKLE BIO-THREATS AND EMERGING DISEASE SOLUTIONSJupiter, Fla. and Nes-Ziona, Israel, Feb. 23, 2024 - Dyadic International, Inc. (NASDAQ: DYAI), a renowned global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has announced an expanded collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm, Life Science Research Israel (LSRI). This partnership aims to leverage Dyadic s expertise in microbial platforms along with IIBR s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseas...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Sources:
Dyadic International Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dyadic International Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
